Lilly’s stock momentum is being fueled by GLP-1 growth, a new oral weight-loss pill, and a push to expand access

Eli Lilly’s shares have drawn renewed attention as investors reassess the company from a traditional drugmaker toward something closer to a sustained “platform” growth story, centered on its incretin franchise of GLP-1-based medicines for obesity and diabetes. In recent weeks, Lilly has highlighted how quickly its flagship treatments are scaling in the market, while also laying out what it says is a path to widen access as competition and pricing pressure increase.

The core of Lilly’s current growth narrative is the demand trajectory for Mounjaro and Zepbound. In its first-quarter 2026 results, Lilly reported revenue of $19.8 billion, up 56% year over year, and raised its full-year 2026 revenue guidance to $82.0 billion to $85.0 billion, along with non-GAAP EPS guidance of $35.50 to $37.00. The company said its quarter included Mounjaro revenue of $8.7 billion, up 125%, and Zepbound U.S. revenue of $4.1 billion, up 79%, noting that lower realized prices partially offset the volume-driven growth.

Lilly is also trying to reduce “choice friction” that can limit adoption of injectable drugs. Its new oral weight-management medicine, Foundayo (orforglipron), received U.S. FDA approval for adults with obesity, or overweight with at least one weight-related medical problem, and Lilly emphasized that it is a GLP-1 pill that can be taken any time of day without food and water restrictions. Lilly called the convenience attribute a meaningful expansion of who can benefit from GLP-1s, and it said eligible patients with commercial insurance may pay as little as $25 per month with a savings card, while self-pay starts at $149 per month for the lowest dose. It also said Medicare Part D beneficiaries may be able to get Foundayo for $50 per month beginning July 1, 2026.

Beyond product launches, Lilly has been working on coverage mechanics. Its Lilly Employer Connect platform, which the company says is launching with more than 15 independent program administrators, is designed to help employers offer obesity coverage in ways that reach patients outside traditional benefit designs. Lilly said its pricing model is intended to lower out-of-pocket barriers for employees, and it disclosed that Zepbound KwikPen will be available from Lilly to network pharmacies at a discounted price of $449 for all doses, with patient costs varying based on employer cost-share models and the program administrator’s structure.

Lilly’s approach is not only defensive, aimed at sustaining momentum for its current GLP-1 franchise, but also offensive, as it tries to build the next wave of therapies. In its first-quarter results release, Lilly said business development included agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics. Separately, Lilly announced terms for its acquisition of Orna Therapeutics, saying Orna shareholders could receive up to $2.4 billion in cash, inclusive of an upfront payment and milestone-based payments, and that Orna is developing circular RNA therapeutics paired with lipid nanoparticles for in vivo generation of cell therapies.

For neuroscience expansion, Lilly’s Centessa deal would bring an orexin receptor 2 (OX2R) agonist pipeline into sleep medicine. Under the definitive agreement described in Centessa’s SEC filing, Lilly will pay $38.00 in cash per Centessa share plus a non-transferable contingent value right that could pay holders up to an additional $9.00 in aggregate based on three U.S. FDA-approval milestones. The lead candidate is cleminorexton (formerly ORX750), aimed at conditions including narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, and the filing said the transaction is expected to close in the third quarter subject to approvals and other customary conditions.

Even with the company’s detailed disclosures on guidance, product access efforts, and deal structures, some uncertainty remains about how much of Lilly’s equity-market rerating will be sustained. The market-focused write-up that sparked the latest discussion attributed the stock strength to a broad reappraisal of long-term growth, but it did not provide primary-source valuation methodology or confirm how much of the rally is driven by expectations versus near-term execution. For investors and analysts, the near-term watch list is whether demand stays robust as pricing evolves, how quickly Foundayo ramps, and whether Lilly’s expansion in access programs and the integration of new acquisitions help translate scientific progress into repeatable commercial performance.